Revolutionizing TRT: MangoRx Introduces Prime, an Oral Testosterone Treatment

Many men aim to improve their athletic performance, increase their energy, and sharpen their cognitive skills. However, for men over the age of 40, achieving these goals can be challenging due to low testosterone levels. Low testosterone impacts millions globally, with a significant portion of men over 40 and 60 being prescribed testosterone replacement therapy (TRT) to enhance libido, energy, and mood. The market for TRT is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2%.

Currently, TRT treatments involve injections, messy gels and creams, or pellets inserted under the skin, all of which can be uncomfortable, embarrassing, and inconvenient. MangoRx aims to revolutionize this with an alternative method to improve men's health without the discomfort.

Mangoceuticals, Inc. (NASDAQ: MGRX), a men's health and wellness telemedicine company known for its erectile dysfunction pill Mango, has introduced a newly FDA-approved oral testosterone replacement therapy called Prime powered by Kyzatrex®. This therapy is clinically proven to restore testosterone to healthy levels with just two oral doses a day with food. Unlike traditional creams or injections, Prime's lymphatic absorption pathway minimizes liver impact and offers consistent absorption unaffected by dietary or alcohol intake.

Prime is marketed to males on other TRT treatments, such as injectables or pellets, and those experiencing symptoms of low testosterone and seeking immediate treatment. MangoRx simplifies the ordering process through its telemedicine platform, where a network of medical providers determines the appropriate dosage and strength after an online telehealth visit. Priced at $224 per month, this uncomplicated process is appealing to the growing customer base.

Prime offers significant value to Mangoceuticals through strong customer retention and recurring revenues. Men tend to remain on TRT long-term, providing consistent revenue streams. MangoRx reported a 108% revenue growth in its first quarter.

The active ingredient in Prime, KYZATREX, is a clinically tested oral testosterone that is up to 96% effective in restoring testosterone levels. In a six-month clinical trial of 139 men with low testosterone, 88% had healthy levels by day 90. Prime's formulation provides balanced hormone levels without the fluctuations typical of injectable therapies, reducing the risk of erythrocytosis and eliminating the need for blood donations as part of treatment management.

The oral testosterone undecanoate in Prime offers additional benefits, including eliminating the need for needles, reducing the risk of infections, and improving bioavailability with fewer liver issues. It provides stable hormone levels, potentially less aromatization to estrogen, and flexible dosing for individual needs. Enhanced well-being, muscle mass, strength, bone density, libido, and sexual function are among the many advantages.

Beyond medical breakthroughs, Prime aims to improve the overall quality of life for men by increasing endurance, strength, energy levels, and physical capabilities. It also enhances mood, mental clarity, focus, and cognitive performance. By positively impacting testosterone levels, Prime contributes to a holistic approach to health and vitality.

Low testosterone is a common condition that can now be treated more comfortably. Prime offers a new, non-invasive option for men looking to improve their overall health and well-being.